Hospitals with a higher volume of percutaneous microaxial ventricular assist device implantation in the US have fewer deaths among cardiogenic shock patients.
Study to be conducted under $3.6 million NIH grant DENVER, Jan. 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), ...
SeaStar Medical (ICU) announced that the U.S. FDA has approved an investigational device exemption application to evaluate ...
Patients with cardiogenic shock treated at hospitals with a higher volume of percutaneous microaxial VAD implantation in the US have lower mortality risk. Higher hospital procedure volume of ...
The ARIES-HM3 trial analysis found that in advanced heart failure patients with traditional indications for antiplatelet ...
of an average age of 2 months (±1.9 months SD), underwent shunt implantation. The size of the ventricular system was described by the Frontal Horn Index and its change after operative procedures ...
This was driven by an increased risk of pneumothorax (1.6% vs 0.8%, P = 0.07) and both atrial and ventricular lead dislodgement/loss of capture (2.0% vs 1.1%, P = 0.07). Early complications were ...
Belarusian cardiologists work real miracles. What transformations in the medical sector does government support prompt?About fifty ...
In a large-animal model study, researchers have found that heart attack recovery is aided by injection of heart muscle cell spheroids derived from human induced pluripotent stem cells, or hiPSCs, that ...
Commonly used devices include implantable cardioverter-defibrillators, devices for cardiac resynchronization therapy, and ventricular assist devices. Catheter-based pulmonary artery denervation ...